Erschienen in:
12.03.2020 | ASO Author Reflections
ASO Author Reflections: mLST8 is a Prognostic Biomarker and Involved in Tumor Progression in Hepatocellular Carcinoma
verfasst von:
Xiang-Nan Yu, MD, Xi-Zhong Shen, MD, PHD, Hong-Ying Guo, MD, Ji-Min Zhu, MD, PHD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 5/2020
Einloggen, um Zugang zu erhalten
Excerpt
Mammalian lethal with sec-13 protein 8 (mLST8) is an essential shared constituent of both mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2, which are the core members of the mTOR pathway.
1 The dysregulation of this pathway is found in many cancers, including hepatocellular carcinoma (HCC).
2 Our previous studies and others have proved that components of this pathway, including eukaryotic translation initiation factor 4E and phosphorylated ribosomal protein S6 kinase B1, were elevated in HCC and associated with adverse prognosis of HCC patients.
2,
3 However, the prognostic effect and biological function of mLST8 remain unknown in HCC. …